Sylvester Comprehensive Cancer Center

  • TAPUR - Calfa, Carmen

  • Investigator:
    Carmen Calfa
    RCname Email

    		Coordinator:

    IRB: 20170529

    		SDG: Precision Medicine
    Disease Site(s):

    Breast,Colon,Kaposis sarcoma,Kidney,Larynx,Liver,Lymphoid Leukemia,Multiple,Multiple Myeloma,Non-Hodgkin Lymphoma,Pancreas,Prostate,Soft Tissue
    Sponsor: ASCO

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester
    Title:

    The Targeted Agent and Profiling Utilization Registry (TAPUR) Study
    Eligibility Criteria - NCT02693535 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230822 - Ikpeazu Chukwuemeka

  • Investigator:
    Chukwuemeka Ikpeazu
    RCname Email

    		Coordinator:

    IRB: 20230822

    		SDG: Precision Medicine
    Disease Site(s):

    Multiple
    Sponsor: NCTN

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester
    Title:

    Molecular Analysis for Combination Therapy Choice (ComboMATCH)
    Eligibility Criteria - NCT05564377 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230838 - Ikpeazu Chukwuemeka

  • Investigator:
    Chukwuemeka Ikpeazu
    RCname Email

    		Coordinator:

    IRB: 20230838

    		SDG: Precision Medicine
    Disease Site(s):

    Multiple
    Sponsor: NRG

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester
    Title:

    Molecular Analysis for Combination Therapy Choice (ComboMATCH) Protocol EAY191-N4: A Randomized Trial of Selumetinib and Olaparib or Selumetinib alone in Patients with recurrent or persistent RAS Pathway Mutant Ovarian and Endometrial Cancers A ComboMATCH Treatment Trial
    Eligibility Criteria - NCT05554328 *This information has been extracted from " www.clinicaltrials.gov"

  • 20231032 - Ikpeazu Chukwuemeka

  • Investigator:
    Chukwuemeka Ikpeazu
    RCname Email

    		Coordinator:

    IRB: 20231032

    		SDG: Precision Medicine
    Disease Site(s):

    Other Digestive Organ
    Sponsor: NCTN

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester
    Title:

    A COMBOMATCH TREATMENT TRIAL: FOLFOX IN COMBINATION WITH BINIMETINIB AS 2ND LINE THERAPY FOR PATIENTS WITH ADVANCED BILIARY TRACT CANCERS WITH MAPK PATHWAY ALTERATIONS
    Eligibility Criteria - NCT05564403 *This information has been extracted from " www.clinicaltrials.gov"

  • 20231427 - Ikpeazu Chukwuemeka

  • Investigator:
    Chukwuemeka Ikpeazu
    RCname Email

    		Coordinator:

    IRB: 20231427

    		SDG: Precision Medicine
    Disease Site(s):

    Pancreas
    Sponsor: Alliance

    Enrolling Sites:

    ABLEH
    Aventura
    Coral Springs
    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester
    UMH
    Title:

    A ComboMATCH Treatment Trial: Palbociclib And Binimetinib In RAS-Mutant Cancers
    Eligibility Criteria - NCT05554367 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230559 - Lopes Gilberto

  • Investigator:
    Gilberto Lopes
    RCname Email

    		Coordinator:

    IRB: 20230559

    		SDG: Precision Medicine
    Disease Site(s):

    Multiple
    Sponsor: PMV Pharmaceuticals Inc

    Enrolling Sites:

    Sylvester
    Title:

    A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
    Eligibility Criteria - NCT04585750 *This information has been extracted from " www.clinicaltrials.gov"

  • 20240715 - Schlumbrecht Matthew

  • Investigator:
    Matthew Schlumbrecht
    RCname Email

    		Coordinator:

    IRB: 20240715

    		SDG: Precision Medicine
    Disease Site(s):

    Ovary
    Sponsor: NRG

    Enrolling Sites:

    Aventura
    Coral Springs
    Deerfield
    Doral
    Gables
    Hollywood
    Kendall
    Plantation
    Sylvester
    UMH
    Title:

    A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination With Palbociclib, a CDK4/6 Inhibitor, in Patients With HER2+ Gynecologic Cancers and Other Solid Tumors: A ComboMATCH Treatment Trial
    Eligibility Criteria - NCT06126276 *This information has been extracted from " www.clinicaltrials.gov"

  • 20240713 - Watson Dionysios

  • Investigator:
    Dionysios Watson
    RCname Email

    		Coordinator:

    IRB: 20240713

    		SDG: Precision Medicine
    Disease Site(s):

    Colon,Lung
    Sponsor: ECOG

    Enrolling Sites:

    Aventura
    Coral Springs
    Deerfield
    Doral
    Gables
    Hollywood
    Kendall
    Plantation
    Sylvester
    UMH
    Title:

    A Randomized Phase II Study of AMG 510 (Sotorasib) with or Without Panitumumab in Advanced Solid Tumors: A ComboMATCH Treatment Trial
    Eligibility Criteria - NCT05638295 *This information has been extracted from " www.clinicaltrials.gov"